Modeling the economic value of a Chagas’ disease therapeutic vaccine

References

• Parasites- American Trypanosomiasis (also known as Chagas Disease). Atlanta: Centers for Disease Control and Prevention, 2010.
   Google Scholar
• Sustainable Development Department. The Millennium Development Goals in Latin America and the Caribbean: Progress, Priorities and IDB Support for Their Implementation. Washington, DC: Inter-American Development Bank, 2005.
   Google Scholar
• Annex Table 3 Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002 In: The World Health Report 2004 -Changing History, ed. Geneva: World Health Organization, 2004.
   Google Scholar
• Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2008; 2:e300; http://dx.doi.org/10.1371/journal.pntd.0000300; PMID: 18820747
   PubMed Web of Science ®Google Scholar
• Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy--where do we stand after a hundred years?. Prog Cardiovasc Dis 2010; 52:300 - 16; http://dx.doi.org/10.1016/j.pcad.2009.11.008; PMID: 20109600
   PubMed Web of Science ®Google Scholar
• Cruz-Reyes A, Pickering-López JM. Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years--a review. Mem Inst Oswaldo Cruz 2006; 101:345 - 54; http://dx.doi.org/10.1590/S0074-02762006000400001; PMID: 16951802
   PubMed Web of Science ®Google Scholar
• Rassi A Jr., Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388 - 402; http://dx.doi.org/10.1016/S0140-6736(10)60061-X; PMID: 20399979
   PubMed Web of Science ®Google Scholar
• Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas’ Disease in the United States. Clin Microbiol Rev 2011; 24:655 - 81; http://dx.doi.org/10.1128/CMR.00005-11; PMID: 21976603
   PubMed Web of Science ®Google Scholar
• Hotez P. Neglected diseases amid wealth in the United States and Europe. Health Aff (Millwood) 2009; 28:1720 - 5; http://dx.doi.org/10.1377/hlthaff.28.6.1720; PMID: 19887412
   PubMed Web of Science ®Google Scholar
• Hotez PJ. Neglected infections of poverty in the United States of America. PLoS Negl Trop Dis 2008; 2:e256; http://dx.doi.org/10.1371/journal.pntd.0000256; PMID: 18575621
   PubMed Web of Science ®Google Scholar
• Quijano-Hernandez I, Dumonteil E. Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin 2011; 7:1184 - 91; http://dx.doi.org/10.4161/hv.7.11.17016; PMID: 22048121
   PubMed Web of Science ®Google Scholar
• Vallejo M, Montenegro P, Reyes PA. [How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital]. Arch Cardiol Mex 2002; 72:129 - 37; PMID: 12148332
   PubMedGoogle Scholar
• Franco-Paredes C, Bottazzi ME, Hotez PJ. The unfinished public health agenda of chagas disease in the era of globalization. PLoS Negl Trop Dis 2009; 3:e470; http://dx.doi.org/10.1371/journal.pntd.0000470; PMID: 19582139
   PubMed Web of Science ®Google Scholar
• Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg 1998; 59:526 - 9; PMID: 9790423
   PubMed Web of Science ®Google Scholar
• de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407 - 13; http://dx.doi.org/10.1016/S0140-6736(96)04128-1; PMID: 8937280
   PubMed Web of Science ®Google Scholar
• Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007; 40:1 - 10; http://dx.doi.org/10.1590/S0037-86822007000100001; PMID: 17486245
   PubMed Web of Science ®Google Scholar
• Basombrío MA, Schofield CJ, Rojas CL, del Rey EC. A cost-benefit analysis of Chagas disease control in north-western Argentina. Trans R Soc Trop Med Hyg 1998; 92:137 - 43; http://dx.doi.org/10.1016/S0035-9203(98)90720-9; PMID: 9764315
   PubMed Web of Science ®Google Scholar
• Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl Trop Dis 2009; 3:e488; http://dx.doi.org/10.1371/journal.pntd.0000488; PMID: 19582142
   PubMed Web of Science ®Google Scholar
• Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, Gamboa-Leon R, et al. Mother-to-child transmission of Chagas’ disease in North America: why don’t we do more?. Matern Child Health J 2008; 12:283 - 6; http://dx.doi.org/10.1007/s10995-007-0246-8; PMID: 17602289
   PubMed Web of Science ®Google Scholar
• Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis 2010; 4:e916; http://dx.doi.org/10.1371/journal.pntd.0000916; PMID: 21179503
   PubMed Web of Science ®Google Scholar
• Sanchez-Burgos G, Mezquita-Vega RG, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, Ouaissi A, et al. Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice. FEMS Immunol Med Microbiol 2007; 50:333 - 41; http://dx.doi.org/10.1111/j.1574-695X.2007.00251.x; PMID: 17521394
   PubMed Web of Science ®Google Scholar
• Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sánchez-Burgos G, Ramirez-Sierra MJ, et al. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Vaccine 2010; 28:7414 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.08.104; PMID: 20850536
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Dumonteil E, Heffernan MJ, Bottazzi ME. Innovation for the 'bottom 100 million': eliminating neglected tropical diseases in the Americas through mass drug administration and new vaccines for hookworm and Chagas disease. Adv Exp Med Biol 2012; In press
   Web of Science ®Google Scholar
• Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 2009; 8:921 - 35; http://dx.doi.org/10.1586/erv.09.45; PMID: 19538117
   PubMed Web of Science ®Google Scholar
• Chongqing Jiachen Biotechnology Ltd. Therapeutic Hepatitis B Vaccine (Synthesized Peptide) in Treating Chronic Hepatitis B Patients. 2011.
   Google Scholar
• Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, et al, AIDS Clinical Trials Group A5187 Team. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 2010; 5:e10555; http://dx.doi.org/10.1371/journal.pone.0010555; PMID: 20479938
   PubMed Web of Science ®Google Scholar
• Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizsäcker G, et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ 2007; 16:491 - 511; http://dx.doi.org/10.1002/hec.1176; PMID: 17013993
   PubMed Web of Science ®Google Scholar
• Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 2010; 28:2806 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.09.047; PMID: 19782109
   PubMed Web of Science ®Google Scholar
• Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007; 102:Suppl 1 75 - 85; http://dx.doi.org/10.1590/S0074-02762007005000093; PMID: 17891282
   PubMed Web of Science ®Google Scholar
• Espinosa R, Carrasco HA, Belandria F, Fuenmayor AM, Molina C, González R, et al. Life expectancy analysis in patients with Chagas’ disease: prognosis after one decade (1973-1983). Int J Cardiol 1985; 8:45 - 56; http://dx.doi.org/10.1016/0167-5273(85)90262-1; PMID: 3997291
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York, 1996.
   Google Scholar
• Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, Martínez MF, et al. The costs of preventing and treating chagas disease in Colombia. PLoS Negl Trop Dis 2008; 2:e336; http://dx.doi.org/10.1371/journal.pntd.0000336; PMID: 19015725
   PubMedGoogle Scholar
• Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010; 51:e69 - 75; http://dx.doi.org/10.1086/656917; PMID: 20932171
   PubMed Web of Science ®Google Scholar
• Frye JE, ed. International Drug Price Indicator Guide. Arlington: Mangement Sciences for Health, Inc., 2009.
   Google Scholar
• The World Bank. GDP per capita (current US$). 2009.
   Google Scholar
• Wilson LS, Strosberg AM, Barrio K. Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models. Am J Trop Med Hyg 2005; 73:901 - 10; PMID: 16282301
   PubMed Web of Science ®Google Scholar
• Pinotti HW, Habr-Gama A, Cecconello I, Felix VN, Zilberstein B. The surgical treatment of megaesophagus and megacolon. Dig Dis 1993; 11:206 - 15; http://dx.doi.org/10.1159/000171413; PMID: 8222303
   PubMed Web of Science ®Google Scholar
• Rassi A Jr., Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq Bras Cardiol 2001; 76:75 - 96; PMID: 11175486
   PubMedGoogle Scholar
• World Health Organization. Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Geneva, 2004.
   Google Scholar